Correction: DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming
Ilaria Gritti(Broad Institute), Nabeel Bardeesy(Broad Institute), Marc N. Wein(Broad Institute), Taranjit S. Gujral(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Joel Markus Vaz(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Songli Zhu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Prabhat Kattel(Broad Institute), John D. Gordan(University of California, San Francisco), Vanessa S. Silveira(Universidade de Ribeirão Preto), Vajira Weeresekara(Brigham Young University), Meng‐Ju Wu(Broad Institute), Phuong Vu(Harvard University), Ashwin V. Kammula(Broad Institute), Krushna C. Patra(University of Cincinnati), Vindhya Vijay(Broad Institute), Jun Qi(Georgia Institute of Technology), Giuseppe Tarantino(Ospedali Riuniti di Ancona), Robert T. Manguso(Broad Institute), Tenna Holgersen Bryde(University of Copenhagen), David Liu(University of Louisville), Marina Chan(Fred Hutch Cancer Center), Jinkai Wan(Massachusetts General Hospital), Christopher J. Ott(Broad Institute), Kei Sakamoto(University of Copenhagen)
Cited by 0
Related Papers
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
|Cell|2018|1.5k
Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
|Nature Medicine|2019|1.1k
Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism
|Nature|2015|788
Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors
|Nature Genetics|2018|701